

## Lamictal XR - (25,50,100,200,250,300 mg; Tablet, Extended Release)

|                              |   |                             |                     |
|------------------------------|---|-----------------------------|---------------------|
| <b>Generic Name</b>          | Lamotrigine   | <b>Innovator</b>            | GlaxoSmithkline     |
| <b>Dosage</b>                | 25,50,100,200,250,300 mg; Tablet, Extended Release  | <b>Branded US Sales</b>     | Less Than \$1000 mn |
| <b>Probable FTF</b>          | Less Than 5   | <b>Known Para IV Filers</b> | Less Than 5         |
| <b>Other ANDA developers</b> | Less Than 5   | <b>Tentative Approvals</b>  | None                |
| <b>Final Approvals</b>       | More Than 5   | <b>Generic Launches</b>     | More Than 5         |
| <b>Indication</b>            | It is an anticonvulsant and mood stabilizer used to treat seizures alone or in combination with other antiepileptic agents. It is used for bipolar disorder and may also have some antidepressant properties. |                             |                     |
| <b>Complexities</b>          | Yes   |                             |                     |

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.